Hoth Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Hoth Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.47M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($8.19M) | Mar 27, 2026 |
| FY2024 | Sep 30, 2024 | ($2.23M) | Mar 28, 2025 |
| FY2024 | Jun 30, 2024 | ($1.71M) | Mar 28, 2025 |
| FY2024 | Mar 31, 2024 | ($2.15M) | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | ($8.11M) | Mar 28, 2025 |
| FY2024 | Sep 30, 2023 | ($2.18M) | Mar 28, 2025 |
| FY2024 | Jun 30, 2023 | ($1.90M) | Mar 28, 2025 |
| FY2024 | Mar 31, 2023 | ($2.24M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($11.37M) | Mar 28, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.36M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($8.22M) | Mar 27, 2026 |
| FY2024 | Sep 30, 2024 | ($2.23M) | Mar 28, 2025 |
| FY2024 | Jun 30, 2024 | ($1.72M) | Mar 28, 2025 |
| FY2024 | Mar 31, 2024 | ($2.16M) | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | ($7.95M) | Mar 28, 2025 |
| FY2024 | Sep 30, 2023 | ($2.18M) | Mar 28, 2025 |
| FY2024 | Jun 30, 2023 | ($1.73M) | Mar 28, 2025 |
| FY2024 | Mar 31, 2023 | ($2.24M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($11.07M) | Mar 28, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.95M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $3.25M | Mar 27, 2026 |
| FY2024 | Sep 30, 2024 | $994.5K | Mar 28, 2025 |
| FY2024 | Jun 30, 2024 | $644.0K | Mar 28, 2025 |
| FY2024 | Mar 31, 2024 | $571.6K | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $3.74M | Mar 28, 2025 |
| FY2024 | Sep 30, 2023 | $1.34M | Mar 28, 2025 |
| FY2024 | Jun 30, 2023 | $664.0K | Mar 28, 2025 |
| FY2024 | Mar 31, 2023 | $942.9K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $4.93M | Mar 28, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.80M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($6.98M) | Mar 27, 2026 |
| FY2024 | Sep 30, 2024 | ($4.95M) | Mar 28, 2025 |
| FY2024 | Jun 30, 2024 | ($3.32M) | Mar 28, 2025 |
| FY2024 | Mar 31, 2024 | ($1.72M) | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | ($8.45M) | Mar 28, 2025 |
| FY2024 | Sep 30, 2023 | ($5.38M) | Mar 28, 2025 |
| FY2024 | Jun 30, 2023 | ($3.74M) | Mar 28, 2025 |
| FY2024 | Mar 31, 2023 | ($2.29M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($9.30M) | Mar 28, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2017 | $3.7K | Apr 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.60M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $7.71M | Mar 27, 2026 |
| FY2024 | Sep 30, 2024 | $8.75M | Mar 28, 2025 |
| FY2024 | Jun 30, 2024 | $10.57M | Mar 28, 2025 |
| FY2024 | Mar 31, 2024 | $9.11M | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $10.24M | Mar 28, 2025 |
| FY2024 | Sep 30, 2023 | $12.90M | Mar 28, 2025 |
| FY2024 | Jun 30, 2023 | $12.83M | Mar 28, 2025 |
| FY2024 | Mar 31, 2023 | $14.39M | Mar 28, 2025 |
| FY2024 | Dec 31, 2022 | $7.74M | Mar 28, 2025 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.45M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $833.9K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $705.0K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.64M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.10M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $597.1K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $440.1K | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $349.0K | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $49.5K | Apr 1, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.15M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $6.88M | Mar 27, 2026 |
| FY2024 | Sep 30, 2024 | $7.94M | Mar 28, 2025 |
| FY2024 | Jun 30, 2024 | $9.88M | Mar 28, 2025 |
| FY2024 | Mar 31, 2024 | $8.45M | Mar 28, 2025 |
| FY2025 | Dec 31, 2023 | $9.54M | Mar 27, 2026 |
| FY2024 | Sep 30, 2023 | $11.32M | Mar 28, 2025 |
| FY2024 | Jun 30, 2023 | $10.86M | Mar 28, 2025 |
| FY2024 | Mar 31, 2023 | $12.80M | Mar 28, 2025 |
| FY2024 | Dec 31, 2022 | $6.11M | Mar 28, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($72.88M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($60.41M) | Mar 27, 2026 |
| FY2024 | Sep 30, 2024 | ($58.31M) | Mar 28, 2025 |
| FY2024 | Jun 30, 2024 | ($56.08M) | Mar 28, 2025 |
| FY2024 | Mar 31, 2024 | ($54.37M) | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | ($52.22M) | Mar 28, 2025 |
| FY2024 | Sep 30, 2023 | ($50.42M) | Mar 28, 2025 |
| FY2024 | Jun 30, 2023 | ($48.25M) | Mar 28, 2025 |
| FY2024 | Mar 31, 2023 | ($46.35M) | Mar 28, 2025 |
| FY2024 | Dec 31, 2022 | ($44.12M) | Mar 28, 2025 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.25M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $7.04M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $9.29M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $6.43M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $8.54M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.63M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $1.69M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $282.6K | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $1.23M | Apr 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 27, 2026 |
| FY2024 | Sep 30, 2024 | 0 | Mar 28, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Mar 28, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | (2) | Mar 28, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 28, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Mar 28, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | (9) | Mar 28, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 27, 2026 |
| FY2024 | Sep 30, 2024 | 0 | Mar 28, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Mar 28, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | (2) | Mar 28, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 28, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Mar 28, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | (9) | Mar 28, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 15.51M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 8.04M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 4.35M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 1.30M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 959,009 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 13.44M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 10.12M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | 5.07M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 4.71M | Apr 1, 2019 |